Amarantus Subsidiary MANF
Therapeutics Announces Issuance of Japanese Patent Covering
Therapeutic Use of MANF in Treatment of Parkinson's Disease
- Issued claims include therapeutic protein, gene therapy and
cell therapy applications
Patent extends MANF Therapeutics' exclusivity for MANF treatment of
Parkinson's disease in Japan into 2029
San Francisco, CA -- December 20, 2017 -- InvestorsHub
NewsWire -- Amarantus Bioscience Holdings, Inc.
(OTCPK:
AMBS), a US-based biotechnology holding company with
wholly-owned subsidiaries developing first-in-class orphan
neurologic, regenerative medicine and ophthalmic therapies, today
announced that its wholly-owned subsidiary MANF Therapeutics, Inc.
was issued a patent by the Japan Patent Office entitled
"Neurodegenerative Disorders" covering the use of MANF as a
treatment for Parkinson's disease. The issued patent extends
coverage for MANF Therapeutics use of MANF in the treatment of
Parkinson's in Japan into 2031.
The key claim issued in this patent is "Use of MANF for the
manufacture of a medicament for administration to the substantia
nigra region of the brain for treating Parkinson's disease." The
substantia nigra is a key area of the brain where dopamine
producing neurons degenerate in Parkinson's disease. Additional
claims covering combinations with MANF and other therapeutic
moieties were also granted, as well as gene therapy and cell
therapy claims. This patent adds to Amarantus' extensive
international intellectual property portfolio covering compositions
of matter, methods of use and formulations for MANF in numerous
disease indications.
Significant pre-clinical efficacy and delivery data supporting
the use of MANF in the treatment of Parkinson's disease is
available in peer-reviewed scientific journals, as well as summary
results that Amarantus previously made publicly available. Certain
data is available at the links below:
A Whitepaper on MANF commissioned by Amarantus in Q2/2013 is
available here: http://content.stockpr.com/amarantus/files/pdf/MANF+WhitePaper+2013-04-30+FINAL.pdf
About Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience Holdings (AMBS) is a biotechnology company
developing treatments and diagnostics for diseases in the areas of
neurology, regenerative medicine and orphan diseases through its
subsidiaries. AMBS' wholly-owned subsidiary Elto Pharma, Inc. has
development rights to eltoprazine, a Phase 2b-ready small molecule
indicated for Parkinson's disease levodopa-induced dyskinesia,
Alzheimer's aggression and adult ADHD. AMBS acquired the rights to
the Engineered Skin Substitute program (ESS), a regenerative
medicine-based approach for treating severe burns with
full-thickness autologous skin grown in tissue culture that is
being pursued by AMBS' wholly-owned subsidiary Cutanogen
Corporation. AMBS' wholly-owned subsidiary MANF Therapeutics, Inc.
owns key intellectual property rights and licenses from a number of
prominent universities related to the development of the
therapeutic protein known as mesencephalic astrocyte-derived
neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing
MANF-based products as treatments for brain and ophthalmic
disorders. MANF was discovered by the Company's Chief Scientific
Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from
AMBS' proprietary discovery engine PhenoGuard. AMBS also owns
approximately 80 million shares of Avant Diagnostics, Inc. via the
sale of its wholly-owned subsidiary Amarantus Diagnostics, Inc.
that occurred in May 2016.
For further information please visit www.Amarantus.com, or connect with the Amarantus on
Facebook, LinkedIn, Twitter and Google+.
About MANF Therapeutics, Inc.
MANF (mesencephalic-astrocyte-derived neurotrophic factor) is
believed to have broad potential because it is a
naturally-occurring protein produced by the body to reduce/prevent
apoptosis (cell death) in response to injury or disease, via the
unfolded protein response. By administering exogenously produced
MANF the body, Amarantus is seeking to use a regenerative medicine
approach to assist the body with higher quantities of MANF when
needed. Amarantus is the front-runner and primary holder of
intellectual property around MANF, and is initially focusing on the
development of MANF-based protein therapeutics.
MANF's lead indication is retinitis pigmentosa, and additional
indications including Parkinson's disease, diabetes and Wolfram's
syndrome are envisioned. Further applications for MANF may include
Alzheimer's disease, traumatic brain injury, myocardial infarction,
antibiotic-induced ototoxicity and certain other orphan
diseases.
In April 2017, Amarantus incorporated the wholly-owned
subsidiary MANF Therapeutics, Inc. to focus on progressing
preclinical and clinical development of MANF.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements. These forward-looking statements
generally are identified by the words "believes," "project,"
"expects," "anticipates," "estimates," "intends," "strategy,"
"plan," "may," "will," "would," "will be," "will continue," "will
likely result," and similar expressions. Forward-looking statements
are based on current expectations and assumptions that are subject
to risks and uncertainties which may cause actual results to differ
materially from the forward-looking statements. Our ability to
predict results or the actual effect of future plans or strategies
is inherently uncertain. Factors which could have a material
adverse effect on our operations and future prospects on a
consolidated basis include, but are not limited to: changes in
economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted
accounting principles. These risks and uncertainties should also be
considered in evaluating forward-looking statements and undue
reliance should not be placed on such statements.
Amarantus Investor and Media Contact:
Ascendant Partners, LLC
Richard Galterio
+1-732-410-9810
rich@ascendantpartnersllc.com
Source: Amarantus Bioscience Holdings, Inc.